Literature DB >> 8686575

[Immunological effect of recombinant interferon-gamma on tumor infiltrating lymphocytes of renal cell carcinoma--relationship with clinical stage].

N Kawata1, Y Takimoto, D Hirano, T Yamamoto, H Hirakata, Y Yamanaka, Y Okada, K Chino, S Sugimoto, T Igarashi.   

Abstract

We studied the relationship between clinical stage and tumor infiltrating lymphocytes (TIL) in 26 cases of renal cell carcinoma. In 10 patients, interferon-gamma (IFN-gamma) was administered preoperatively (administration group); 5 patients had low stage (Robson < or = I), and the remaining 5 patients had high stage (Robson > or = II) tumors. The other 16 patients underwent nephrectomy alone without preoperative IFN administration (control group); 11 patients had low stage, and the remaining 5 patients had high stage tumors. Immunohistochemical studies of tumor infiltrating lymphocytes in renal cell carcinoma showed a significantly high incidence of CD3, CD8, CD11b and ICAM-1 in the administration group, while CD4, LFA-1 and Ber-MAC3 were increased without significance (p < 0.05). Concerning clinical stage (Robson), a significant increase in CD3, CD8, CD11b and ICAM-1 was observed in the patients with high-stage tumors in the administration group compared to those in the control group (p < 0.05). This suggested that TIL could be changed by preoperative administration of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686575

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Prognostic histological and immune markers of renal cell carcinoma.

Authors:  T Magyarlaki; I Buzogány; L Kaiser; F Sükösd; R Döbrönte; B Simon; A Fazekas; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

2.  Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.

Authors:  T Magyarlaki; I Buzogány; J Nagy
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.